AbCellera director granted 111,701 share options

AbCellera Biologics Inc. director Michael R. Hayden received a grant of share options covering 111,701 common shares.

Rhea-AI Filing Summary

AbCellera Biologics Inc. director Michael R. Hayden received a grant of share options covering 111,701 common shares. The options have an exercise price of $5.27 per share, expire on June 11, 2036, and represent compensation rather than an open-market purchase.

The options vest and become exercisable at the company’s 2027 Annual General Meeting, subject to his continuous service with AbCellera through that date. Following this award, he holds options on a total of 1,011,544 underlying common shares directly.

Insider Trade Summary

Grant/Award: 111,701 shares

Grant/Award 1 txn

Insider Hayden Michael R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share option (right to buy)	111,701	$0.00	$0.00

Holdings After Transaction: Share option (right to buy) — 1,011,544 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Options granted: 111,701 shares Exercise price: $5.27 per share Expiration date: June 11, 2036 +2 more

5 metrics

Options granted 111,701 shares Share option grant to director on June 11, 2026

Exercise price $5.27 per share Strike price of newly granted options

Expiration date June 11, 2036 Option term for this grant

Total options after grant 1,011,544 shares Underlying common shares following this award

Vesting event 2027 Annual General Meeting Options vest at 2027 AGM if service continues

Key Terms

Share option (right to buy), exercise price, expiration date, Annual General Meeting

4 terms

Share option (right to buy) financial

"security_title: "Share option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "5.2700" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Annual General Meeting financial

"vest and become exercisable at the 2027 Annual General Meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AbCellera (ABCL) director Michael R. Hayden report on this Form 4?

Director Michael R. Hayden reported receiving a grant of share options for 111,701 AbCellera common shares. This is a compensation-related award, not an open-market trade, and increases his directly held option-based exposure to the company’s stock.

What are the key terms of Michael R. Hayden’s AbCellera share option grant?

The grant covers 111,701 AbCellera common shares at an exercise price of $5.27 per share. The options expire on June 11, 2036, giving Hayden a long exercise window once they vest and become exercisable.

When do Michael R. Hayden’s newly granted AbCellera options vest?

The options vest and become exercisable at AbCellera’s 2027 Annual General Meeting. Vesting is conditioned on Hayden’s continuous service to the company through that date, aligning the award with his ongoing board role.

How many AbCellera shares could Michael R. Hayden acquire after this option grant?

After this grant, Hayden holds options linked to 1,011,544 AbCellera common shares in total. This figure includes the newly awarded 111,701-share option, reflecting his full direct derivative position reported in this Form 4.

Does this AbCellera Form 4 show any stock sales or purchases by Michael R. Hayden?

The Form 4 shows no stock sales or open-market purchases by Hayden. It reports only a grant of share options as compensation, classified as a derivative acquisition rather than a buy or sell transaction in the company’s common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 01:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hayden Michael R

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	$5.27	06/11/2026		A	V	111,701		06/10/2027(1)	06/11/2036	Common Shares	111,701	$0	1,011,544	D

Explanation of Responses:

1. The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	Tryn Stimart, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)